Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors

Trial Title: Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors

NCT ID: NCT00870129

Condition: Brain Cancer
Glioma

Conditions: Official terms:
Glioma
Brain Neoplasms

Conditions: Keywords:
brain tumor
radiation
MRI
09-009

Study type: Interventional

Study phase: N/A

Overall status: Recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Diagnostic

Masking: None (Open Label)

Intervention:

Intervention type: Procedure
Intervention name: MRI and advanced MRI sequences
Description: This is a nonrandomized study in which each patient will receive the standard clinical care (in the form of surgery, radiation therapy and/or chemotherapy), as per the treating physician. Surgical resection will be performed at the discretion of the treating Neurooncologist and/or Neurooncology Tumor Board. Advanced brain MRIs with the 2 (or, in some cases, 3) special sequences will be obtained at the time of the clinically scheduled contrast MRIs, which are usually obtained immediately prior to and 1 months±3 weeks after radiation therapy if the patient requires radiation therapy for his/her tumor. The advanced brain MRI may also be obtained before surgery for suspected or confirmed gliomas, as per the standard of care, in some patients who may or may not require radiation therapy.
Arm group label: MRI

Summary: The researchers think that the use of advanced MR imaging may help people with this disease, because it may better predict areas within a malignant glioma (brain tumor) that are at a high risk of recurring. WeThe reserchers are doing this study to see whether this advanced imaging is a safe treatment that causes few or mild side effects in people with brain tumors.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Suspected or Histopathologically proven diagnosis of high grade or low glioma or tumor is suspected to harbor an isocitrate dehydrogenase (IDH) mutation - May undergo radiation therapy - Patient and/or guardian is able to provide written informed consent prior to study registration - Age ≥ 18 years old Exclusion Criteria: - Extreme claustrophobia that precludes MRI scan - Known allergic reaction to Gd-DTPA - Any contraindication to gadolinium intravenous contrast as per standard Department of Radiology contrast guidelines - Any absolute contraindication to MRI (e.g., pacemaker, aneurysm clip, tissue expander). - Pregnant or nursing female - Unable to cooperate for MRI and/or radiation therapy planning

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Memorial Sloan Kettering Cancer Center

Address:
City: New York
Zip: 10065
Country: United States

Status: Recruiting

Contact:
Last name: Robert Young, MD

Phone: 212-639-8196

Contact backup:
Last name: Sunitha Thakur, PhD

Investigator:
Last name: Robert Young, MD
Email: Principal Investigator

Start date: March 2009

Completion date: September 2025

Lead sponsor:
Agency: Memorial Sloan Kettering Cancer Center
Agency class: Other

Source: Memorial Sloan Kettering Cancer Center

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT00870129
http://www.mskcc.org